European Commission
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
17:00 Brussels time
Last verified:
This Horizon Europe RIA funds pragmatic clinical trials testing immunotherapeutic interventions for patients with refractory cancers, with grants of €7-€8 million in lump-sum format. Proposals must be led by academic investigators and include a mandatory clinical studies annex, structured engagement of patients in endpoint definition, and disaggregated outcome reporting by sex, gender, and age. Applicants must assemble a consortium of at least three entities across three EU member states and commit to the EU Cancer Mission 'Diagnosis and Treatment' cluster.
Details
| Funder | European Commission |
| Budget | €7M–€8M per grant |
| Deadline | 15 September 2026 |
| Consortium | Required — minimum 3 entities from 3 EU member states |
| Application | Single-stage |
| Frequency | One-off |
Eligibility & scope
Horizon Europe RIA (lump sum) for academic investigator-initiated pragmatic clinical trials on immunotherapeutic interventions for refractory cancer patients. Proposals must include a clinical studies annex, disaggregate data by sex/gender/age, and engage patients in endpoint definition. Applicants must include diverse stakeholders and plan to join the EU Cancer Mission 'Diagnosis and Treatment' cluster. ~3 grants expected.
Who Should Apply
- •Academic investigator-led teams with experience in clinical trial design and oncology
- •Consortia spanning at least 3 EU member states with diversity of stakeholders (clinicians, researchers, patient groups, industry partners)
- •Teams committed to pragmatic trial methodology and disaggregated outcome analysis by sex, gender, and age
- •Applicants with existing or planned engagement pathways for patient involvement in endpoint definition
Key Dates
- •Deadline: 15 September 2026, 17:00 Brussels time
- •Single-stage evaluation
- •Approximately 3 grants expected
Tips for Applicants
- ✓The clinical studies annex is mandatory and carries substantial weight, develop it early with your clinical partners; vague protocols will stall review.
- ✓Patient engagement in endpoint definition is scored explicitly; document concrete meetings, feedback mechanisms, and how patient input shaped your primary and secondary endpoints.
- ✓EU Cancer Mission alignment is a gate: confirm your proposal's fit to the 'Diagnosis and Treatment' cluster objectives early and cite relevant strategic partnership documents.
Frequently Asked Questions
How much funding does this Horizon Europe RIA grant for cancer clinical trials offer?
Up to €7-€8 million per grant in lump-sum format.
Do I need a consortium to apply for this cancer immunotherapy clinical trial grant?
Yes, consortia must include a minimum of 3 entities from 3 different EU member states.
What is a pragmatic clinical trial in the context of this call?
The call funds real-world, investigator-initiated trials testing immunotherapeutic interventions in refractory cancer populations, with mandatory patient involvement in endpoint design and disaggregated outcome reporting.
Who can lead a proposal for this cancer clinical trial grant?
Academic investigators must lead proposals; clinicians, researchers, patient representatives, and industry partners may participate as consortium members.
How many grants will be awarded in this call?
Approximately 3 grants are expected.
Related on Grantsby
- European Commission writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
More from European Commission
Marie Sklodowska-Curie Actions (MSCA) Postdoctoral Fellowships 2026
Deadline: 9 Sept 2026Marie Skłodowska-Curie Actions Postdoctoral Fellowships (MSCA-PF) 2026
Deadline: 9 Sept 2026HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships (HORIZON-TMA-MSCA-PF-EF)
Deadline: 9 Sept 2026HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships (HORIZON-TMA-MSCA-PF-GF)
Deadline: 9 Sept 2026Cancer Mission Ria – Horizon-Miss-2026-02-Cancer-02
Deadline: 15 Sept 2026Around €15M
Browse Related
Could Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →